275 related articles for article (PubMed ID: 21147872)
1. The utility of BRAF testing in the management of papillary thyroid cancer.
Melck AL; Yip L; Carty SE
Oncologist; 2010; 15(12):1285-93. PubMed ID: 21147872
[TBL] [Abstract][Full Text] [Related]
2. BRAF in papillary thyroid carcinoma.
Lanzilotta SG; Grammatica L; Paradiso A; Simone G
Cell Oncol; 2007; 29(4):269-77. PubMed ID: 17641411
[TBL] [Abstract][Full Text] [Related]
3. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
4. [BRAF initiating mutations in the papillary thyroid carcinoma].
Rusinek D; Gubała E
Endokrynol Pol; 2006; 57(4):438-44. PubMed ID: 17006850
[TBL] [Abstract][Full Text] [Related]
5. Prognostic utility of BRAF mutation in papillary thyroid cancer.
Xing M
Mol Cell Endocrinol; 2010 May; 321(1):86-93. PubMed ID: 19883729
[TBL] [Abstract][Full Text] [Related]
6. [The co-relation of BRAF V600E mutation and factors affecting occurrence and prognosis of papillary thyroid carcinoma].
Wang J; Liu LT; Cui D; He L; Liu DG
Zhonghua Bing Li Xue Za Zhi; 2019 Apr; 48(4):288-292. PubMed ID: 30955264
[No Abstract] [Full Text] [Related]
7. Molecular Alterations in Thyroid Carcinoma.
Haroon Al Rasheed MR; Xu B
Surg Pathol Clin; 2019 Dec; 12(4):921-930. PubMed ID: 31672298
[TBL] [Abstract][Full Text] [Related]
8. [Use of BRAF V600E mutation in the differential diagnosis of follicular and papillary tumors of the thyroid and for the optimization of thearpy].
Semënov DIu; Boriskova ME; Zaraĭskiĭ MI; Saburova IIu; Pankova PA; Farafonova UV; Bykov MA
Vopr Onkol; 2012; 58(5):649-52. PubMed ID: 23600282
[TBL] [Abstract][Full Text] [Related]
9. BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma.
Rossi ED; Martini M; Capodimonti S; Lombardi CP; Pontecorvi A; Vellone VG; Zannoni GF; Larocca LM; Fadda G
Cancer Cytopathol; 2013 Jun; 121(6):291-7. PubMed ID: 23192956
[TBL] [Abstract][Full Text] [Related]
10. Clinical Utility of BRAF, NRAS, and TERT Promoter Mutation in Preoperative Thyroid Fine-Needle Aspiration Biopsy: A Diagnostic Study From Dharmais Cancer Hospital.
Perdana AB; Putri RI; Rachmawati R; Andinata B; Brahma B
Asian Pac J Cancer Prev; 2020 Nov; 21(11):3267-3277. PubMed ID: 33247684
[TBL] [Abstract][Full Text] [Related]
11. Role of gene expression profiling in defining indeterminate thyroid nodules in addition to BRAF analysis.
Borrelli N; Ugolini C; Giannini R; Antonelli A; Giordano M; Sensi E; Torregrossa L; Fallahi P; Miccoli P; Basolo F
Cancer Cytopathol; 2016 May; 124(5):340-9. PubMed ID: 26749005
[TBL] [Abstract][Full Text] [Related]
12. Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer.
Lee MY; Ku BM; Kim HS; Lee JY; Lim SH; Sun JM; Lee SH; Park K; Oh YL; Hong M; Jeong HS; Son YI; Baek CH; Ahn MJ
Cancer Res Treat; 2017 Oct; 49(4):906-914. PubMed ID: 28052655
[TBL] [Abstract][Full Text] [Related]
13. Detection of BRAF c.1799T > A (p.V600E) mutation using residual routine fine-needle aspiration specimens of papillary thyroid carcinoma.
Zhao H; Zhang ZH; Zhou B; Xiao T; Pan QJ; Guo HQ
Diagn Cytopathol; 2015 Oct; 43(10):786-90. PubMed ID: 26152656
[TBL] [Abstract][Full Text] [Related]
14. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
Krishnamurthy A; Ramshankar V; Murherkar K; Vidyarani S; Raghunandhan GC; Das A; Desai PB; Albert K
Indian J Cancer; 2017; 54(1):372-378. PubMed ID: 29199726
[TBL] [Abstract][Full Text] [Related]
15. B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas.
Trovisco V; Soares P; Sobrinho-Simões M
Hum Pathol; 2006 Jul; 37(7):781-6. PubMed ID: 16784975
[TBL] [Abstract][Full Text] [Related]
16. The prevalence and prognostic value of BRAF mutation in thyroid cancer.
Kebebew E; Weng J; Bauer J; Ranvier G; Clark OH; Duh QY; Shibru D; Bastian B; Griffin A
Ann Surg; 2007 Sep; 246(3):466-70; discussion 470-1. PubMed ID: 17717450
[TBL] [Abstract][Full Text] [Related]
17. BRAF genetic heterogeneity in papillary thyroid carcinoma and its metastasis.
Walts AE; Pao A; Sacks W; Bose S
Hum Pathol; 2014 May; 45(5):935-41. PubMed ID: 24746198
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of molecular diagnostic approaches for the detection of BRAF p.V600E mutations in papillary thyroid cancer: Clinical implications.
Kowalik A; Kowalska A; Walczyk A; Chodurska R; Kopczyński J; Chrapek M; Wypiórkiewicz E; Chłopek M; Pięciak L; Gąsior-Perczak D; Pałyga I; Gruszczyński K; Nowak E; Góźdź S
PLoS One; 2017; 12(6):e0179691. PubMed ID: 28636673
[TBL] [Abstract][Full Text] [Related]
19. BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications.
Tang KT; Lee CH
J Chin Med Assoc; 2010 Mar; 73(3):113-28. PubMed ID: 20230995
[TBL] [Abstract][Full Text] [Related]
20. Clinical implications of BRAF mutation in thyroid carcinoma.
Puxeddu E; Durante C; Avenia N; Filetti S; Russo D
Trends Endocrinol Metab; 2008; 19(4):138-45. PubMed ID: 18337114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]